<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00943345</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 09-3-034</org_study_id>
    <nct_id>NCT00943345</nct_id>
  </id_info>
  <brief_title>Validation of New Tests for Gastrointestinal (GI) Permeability</brief_title>
  <acronym>Permeability</acronym>
  <official_title>Dubbelblind Crossover Study for Validation of New Tests for Gastrointestinal (GI) Permeability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Top Institute Food and Nutrition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: The primary function of the gastrointestinal (GI) wall is digestion and
      absorption of nutrients that are important for growth and development. The second important
      function of the GI wall is forming an effective barrier to prevent penetration of potentially
      harmful components from the inside of the gut (lumen), via the GI wall, into the body.

      A compromised barrier function may play an important role in the development of a range of
      inflammatory GI diseases such as coeliac disease, Inflammatory Bowel Disease (IBD), food
      allergy, but also in the pathophysiology of postoperative complications. It is important and
      clinically relevant to have reliable GI permeability tests, however the existing test leave
      room for improvement.

      Rationale/aim: Three new tests are developed to assess gastrointestinal permeability in both
      normal controls with and without raised permeability, and in patients with coeliac disease.
      In the current study these new permeability tests will be evaluated and compared with the
      golden standard permeability test, the dual sugar test.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">February 2012</completion_date>
  <primary_completion_date type="Anticipated">February 2012</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of permeability tests (new versus golden standard dual sugar test)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GI permeability</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Gastrointestinal Diseases</condition>
  <arm_group>
    <arm_group_label>GS dual sugar permeability test</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Golden standard GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).
Coeliac patients will only have 1 test to assess basal GI permeability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi sugar test</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).
Coeliac patients will only have 1 test to assess basal GI permeability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protein test</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).
Coeliac patients will only have 1 test to assess basal GI permeability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG test</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).
Coeliac patients will only have 1 test to assess basal GI permeability.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indometacin</intervention_name>
    <description>capsule for oral consumption
at 22h00 evening before test day: 75 mg
at 7h30 on the test day: 50 mg This intervention will be applied 4 times (4 arms).</description>
    <arm_group_label>GS dual sugar permeability test</arm_group_label>
    <arm_group_label>Multi sugar test</arm_group_label>
    <arm_group_label>Protein test</arm_group_label>
    <arm_group_label>PEG test</arm_group_label>
    <other_name>Indometacin [Actavis]</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy controls, female/male, 18-75 years of age, OR:

          -  coeliac disease without taking medicine, female/male, 18-75 years of age

        Exclusion Criteria:

          -  cardiac and/or vascular disease

          -  chronic obstructive pulmonary disease (COPD)

          -  rheumatic arthritis (RA)

          -  Inflammatory bowel disease(IBD); Crohn's colitis or colitis ulcerosa

          -  Irritable bowel syndrome (IBS)

          -  Inflammatory systemic disease

          -  Obesity (Body Mass Index ≥ 30 kg/m²)

          -  Diabetes Mellitus

          -  Thyroid disease

          -  Kidney disease

          -  Cancer

          -  Smoking

          -  Substance abuse (alcohol, drug, cocain, opioids, and others)

          -  Use of drugs

          -  Operations to the GI system, apart from appendectomy

          -  Allergy to eggs or milk

          -  Hypersensitivity to any of the following: lactulose, l-rhamnose, sucrose, sucralose of
             erythritol

          -  Acute porphyria or phenylketonuria (PKU)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WA Buurman, Prof.dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Zuid-Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2009</study_first_submitted>
  <study_first_submitted_qc>July 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2009</study_first_posted>
  <last_update_submitted>November 7, 2011</last_update_submitted>
  <last_update_submitted_qc>November 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maastricht University Medical Center</investigator_affiliation>
    <investigator_full_name>Kim van Wijck</investigator_full_name>
    <investigator_title>MD, PhD student</investigator_title>
  </responsible_party>
  <keyword>GI</keyword>
  <keyword>gastrointestinal</keyword>
  <keyword>permeability</keyword>
  <keyword>indometacin</keyword>
  <keyword>indomethacin</keyword>
  <keyword>coeliac</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

